Pharmacology & Therapeutics

Papers
(The H4-Index of Pharmacology & Therapeutics is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue395
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption392
Editorial Board286
Collateral lethality: A unique type of synthetic lethality in cancers274
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis244
Adenosine receptor signalling as a driver of pulmonary fibrosis226
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy210
Inflammation, lipids, and pain in vulvar disease190
Exploiting the obesity-associated immune microenvironment for cancer therapeutics183
Potential neonatal toxicity of new psychoactive substances182
The role of macrophages in asthma-related fibrosis and remodelling166
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis155
Endothelial dysfunction as a complication of anti-cancer therapy154
In cancer, all roads lead to NADPH149
Matrikines in the skin: Origin, effects, and therapeutic potential138
Unfolded protein responses: Dynamic machinery in wound healing137
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target122
Non-canonical G protein signaling120
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications120
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions118
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression118
TAAR1 as an emerging target for the treatment of psychiatric disorders117
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy116
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases114
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives107
Boron in cancer therapeutics: An overview105
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?104
Contribution of non-selective membrane channels and receptors in epilepsy101
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond95
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance92
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics89
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization88
Cell-based therapies for vascular regeneration: Past, present and future87
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors86
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved85
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases84
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets81
Dysregulation of metabolic pathways in pulmonary fibrosis80
TLR4 biased small molecule modulators79
Pharmacological treatment of cardiogenic shock – A state of the art review79
Natural products that alleviate depression: The putative role of autophagy78
Bispecific antibodies for the treatment of neuroblastoma78
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]76
Editorial Board75
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)74
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents74
Review: Sex-related differences in the treatment of cardiac arrhythmia73
Wnt signaling: A prospective therapeutic target for chronic pain71
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance70
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy69
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain69
PGRMC1: An enigmatic heme-binding protein69
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease66
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression66
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors66
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms66
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy65
DNA methylation in cell plasticity and malignant transformation in liver diseases65
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer64
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response64
Addiction and the kynurenine pathway: A new dancing couple?63
Stabilizing the neural barrier – A novel approach in pain therapy62
0.59130811691284